Celldex Therapeutics, Inc.
NASDAQCelldex Therapeutics heads into its June 25 earnings with short sellers rebuilding positions, UBS lifting its target on the day, and the stock still down sharply from its month-ago levels. The most telling tension this week is the divergence between short-term price recovery and the medium-term short rebuild. The stock gained 2.4% on the week to $29.60, clawing back ground after a…
Snapshot as of 28 Jun 2026
Celldex Therapeutics heads into its June 25 earnings with short sellers rebuilding positions, UBS lifting its target on the day, and the stock still down sharply from its month-ago levels. The most telling tension this…
Celldex Therapeutics enters the post-earnings stretch with a striking split: short sellers are unwinding at pace while the analyst community shifts decisively more constructive, yet the stock is still down 5.5% on the…
Celldex Therapeutics reports Q1 2026 results on May 11 with short sellers maintaining a meaningful position — but the borrow market tells a story of fading conviction rather than escalating pressure. Short interest is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CLDX — free to start on ORTEX.
Sign up for free →Open CLDX on ORTEX